Key Highlights

  • Published market data showed Pacific Biosciences (NASDAQ:PACB) up 5.13% at USD 2.57 on Volume of 7.452 million shares; the snapshot date is not shown and the figures are unverified.
  • Second quarter 2026 Revenue was USD 39.0 million, down from USD 39.8 million a year earlier, with a GAAP net loss of USD 44.7 million, or USD 0.14 per share.
  • Cash, cash equivalents and investments were USD 236.9 million at June 30, 2026, against USD 314.7 million a year earlier, per the company release.
  • Full-year 2026 revenue guidance was USD 155 million to USD 165 million after the August 5, 2026 report; the first quarter release had pointed to USD 165 million to USD 175 million.

Third Quarter Report Due November 4, 2026

Pacific Biosciences (NASDAQ:PACB) has scheduled its third quarter 2026 results and a conference call for November 4, 2026. The numbers had not been verified when this was written, so this is a preview, not a result. Published market data showed a 5.13% gain at USD 2.57 with 7.452 million shares traded, but the snapshot date is unknown. The company makes long-read DNA sequencing instruments and consumables for genomics researchers, with Revio and Vega systems used in research and clinical labs. In the second quarter it placed 20 Revio systems, up from 15, and 26 Vega systems, down from 38.

Margins, Cash Burn and a Guidance Trim

The August 5, 2026 release showed consumables revenue of USD 20.1 million, instruments of USD 12.8 million and service and other of USD 6.1 million. GAAP gross Margin was 32% and non-GAAP was 36%, both lower year over year, which the company tied to compute and memory costs, Vega Manufacturing transition costs and lower Revio selling prices on multi-system deals. Cash fell by about USD 77.8 million from the year-earlier balance (simple arithmetic on two published numbers). The company also announced a restructuring to streamline Marketing and research, and the first quarter filing showed convertible senior notes of USD 644.1 million, net.

Penny Stock Trading Risks Around the Print

Even with a Nasdaq listing, a Penny Stock can move sharply on a small number of trades, and spreads can widen around results. A quoted gain may reverse once the report is public, and nothing here implies the move will continue. Investors will likely watch placements of Revio and Vega, the SPRQ-Nx chemistry rollout priced at USD 345 per genome, gross margin direction, and whether the USD 155 million to USD 165 million revenue range holds. The Basecamp Research population-scale program, the largest of its kind for the company to date, is another item it highlighted, with sequencing and sample delivery already under way.

Where Things Stand

The 5.13% gain looks like pre-earnings positioning on a low-priced stock, not a verified reaction to news. Pacific Biosciences (NASDAQ:PACB) reports on November 4, 2026, and the last verified figures show flat revenue, a USD 44.7 million quarterly loss and falling cash. The screen price and move are unverified and undated, so they should not be read as a reaction to any specific event. The company must also manage a large convertible note balance against a shrinking cash pile. The next catalyst is the report itself, where guidance, margins and cash will matter more than the quoted gain.